News
Emerging therapies targeting GD2, a marker highly expressed in neuroblastoma, offer tremendous promise. FDA-approved ...
Buildout includes Gerteis Macro-Pactor install to meet growing demand for complex oral solid dose development and manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback